Grown Rogue International (GRUSF) Net Income towards Common Stockholders (2009 - 2026)
Grown Rogue International's (GRUSF) quarterly Net Income towards Common Stockholders came in at -$99657.0 in Q1 2026, up 100.0% quarter-over-quarter from -$5914.4 billion in Q4 2025.
Grown Rogue International (GRUSF) Net Income towards Common Stockholders (2009 - 2026) Analysis & Trends
Grown Rogue International's Net Income towards Common Stockholders history runs 18 years deep, the most recent figure standing at -$99657.0 for Q1 2026.
- On a quarterly basis, Net Income towards Common Stockholders changed N/A year-over-year to -$99657.0 in Q1 2026; TTM through Mar 2026 was -$3216.1 billion, a 51816912.22% decrease from a year earlier, with the FY2025 full-year figure at -$452962.0, down 80.3% from the prior year.
- Net Income towards Common Stockholders rose to -$99657.0 in Q1 2026 per GRUSF's latest filing, from -$5914.4 billion in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $2698.3 billion in Q3 2025 and bottomed at -$5914.4 billion in Q4 2025.
- The 5-year median for Net Income towards Common Stockholders is $52766.7 (2026), against an average of -$268.0 billion.
- Across the five-year window, Net Income towards Common Stockholders jumped 60.73% in 2022 and soared 460970719.11% in 2025, its largest moves.
- Year by year, Net Income towards Common Stockholders stood at -$422824.0 in 2022, then surged by 259.03% to $672427.0 in 2023, then slumped by 187.05% to -$585354.9 in 2024, then sank by 1010400416.04% to -$5914.4 billion in 2025, then soared by 100.0% to -$99657.0 in 2026.
- Per Business Quant, the three latest GRUSF Net Income towards Common Stockholders figures stand at -$99657.0 (Q1 2026), -$5914.4 billion (Q4 2025), and $2698.3 billion (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | -2.35 Bn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 274.90 Mn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Grown Rogue International | 99.32 Mn | 85.61 Mn | 3.96 Mn | -99,657.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -99,657.00 |
| Dec 31, 2025 | -5,914.43 Bn |
| Sep 30, 2025 | 2,698.31 Bn |
| Jun 30, 2025 | 1.32 Mn |
| Sep 30, 2024 | -585,354.88 |
| Jun 30, 2024 | -5.62 Mn |
| Dec 31, 2023 | 672,427.00 |
| Oct 31, 2023 | -1.56 Mn |
| Jul 31, 2023 | 205,190.44 |
| Apr 30, 2023 | 412,846.00 |
| Jan 31, 2023 | 931,945.00 |
| Jan 31, 2022 | -422,824.00 |
| Jul 31, 2021 | -54,533.00 |
| Apr 30, 2021 | -1.15 Mn |
| Jan 31, 2021 | -1.08 Mn |
| Oct 31, 2020 | 26,352.00 |
| Jul 31, 2020 | -798,200.00 |
| Apr 30, 2020 | -1.29 Mn |
| Jan 31, 2020 | -1.61 Mn |
| Oct 31, 2019 | -2.09 Mn |